使用两种第二代酶联免疫吸附试验检测血液透析患者中的丙型肝炎病毒抗体
Detection of antibodies to HCV in haemodialysis patients using two second generation ELISA tests.
作者信息
Dentico P, Volpe A, Buongiorno R, Fiore G, Carbone M, Manno C, Pastore G, Schiraldi O
机构信息
Istituto Policattedra Clinica Medica e Malattie Infettive, Università di Bari, Italy.
出版信息
Ital J Gastroenterol. 1993 Jan;25(1):19-22.
Ortho HCV Elisa Test System 2nd Generation and Abbott HCV EIA 2nd Generation tests were used in 293 sera collected from dialysis patients in order to determine the prevalence of anti-HCV in this risk group and the sensitivity of the two tests. The agreement between the two tests employed was 98.3%. All reactive sera were confirmed using Ortho Riba and Abbott Supplemental tests. 91.9% sera were confirmed positive by Ortho RIBA and 100% by Abbott Supplemental test. The anti-HCV prevalence in haemodialysis patients increased with age, duration of dialysis treatment and number of transfusions. Our study confirms the higher prevalence of anti-HCV in haemodialysis patients using 2nd generation tests and their specificity.
使用第二代Ortho HCV酶联免疫吸附试验系统和雅培第二代HCV酶免疫测定法对293份来自透析患者的血清进行检测，以确定该风险人群中抗HCV的流行率以及这两种检测方法的灵敏度。所采用的两种检测方法之间的一致性为98.3%。所有反应性血清均使用Ortho Riba和雅培补充试验进行确认。91.9%的血清经Ortho RIBA确认为阳性，经雅培补充试验确认为阳性的比例为100%。血液透析患者中抗HCV的流行率随年龄、透析治疗时间和输血次数的增加而升高。我们的研究证实了使用第二代检测方法时血液透析患者中抗HCV的流行率较高及其特异性。
Zotero 插件